肠促胰素的胰腺外作用研究进展(5)

19.Plutzky J;Garber A;Toft AD Meta-analysis demonstrates that liraglutide,a once-daily human GLP-1analogue,significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes2009(Suppl 1)

20.Nystrom T;Gutniak MK;Zhang DM Effects of glucagon-like poptide-1 on endothelial function in type2 diabetes patients with stable coronary artery disease 2004

21.Yu M;Moreno C;Hoagland KM Antihypertensive effect of glucagonlike peptidel in Dahl salt-sensitiverats[外文期刊] 2003(6)

22.Fonseca V In subjects with type 2 diabetes,liraglutide,a once-daily human GLP-I analogue,reducessystolic blood pressure with negligible impact from weight loss 2010(Suppll)

23.Fonseca V Liraglutide,a Once-Daily Human GLP-I Analog,Lowers Systolic Blood Pressure (SBP)Independently of Concomitant Antihypertensive Treatment 2010(Suppll)

24.Grieve DJ;Cassidy RS;Green BD Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1:potential therapeutic benefits beyond glycaemic control[外文期刊] 2009

25.Nauck MA;Barrels E;Orskov C Lack of effect of synthetic human gastric inhibitory polypeptide andglucagon-like peptide 1[7-36 amide]infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects[外文期刊] 1992

26.Merchenthaler I;Lane M;Shughrue P Distribution of pre-pro-glucagon and glucagon-like peptide-1receptor messenger RNAs in the rat central nervous system[外文期刊] 1999

27.Dupre J;Behme MT;Hramiak IM Glucagon-like peptide I reduces postprandial glycemic excursions inIDDM[外文期刊] 1995

28.Nauck MA;Wollschlǎger D;Wemer J Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36amide]) in patients with NIDDM[外文期刊] 1996

29.Meier JJ;Gallwitz B;Salmen S Normalization of glucose concentrations and deceleration of gastricemptying after solid meals during intravenous glucagon-like peptidel in patients with type 2diabetes[外文期刊] 2003

30.Willms B;Weruer J;Hoist JJ Gastric emptying,glucose responses,and insulin secretion after aliquid test meal:effects of exogenous glucagon-likc peptide-1 (GLP-1) -(7-36) amide in type 2(noninsulindependent) diabetic patients[外文期刊] 1996(1)

31.Nauck MA;Niedereichholz U;Ettler R Glucagon-like peptide 1 inhibition of gastric emptyingoutweighs its insulinotropic effects in healthy humans 1997

hippecampus and induces progenitor cell proliferation[外文期刊] 2005(7)

33.Zander M;Madsbad S;Madsen JL Effect of 6-weck course of glucagonlike peptide 1 on glycacmiccontrol,insulin sensitivity,and β-cell function in type 2 diabetes:a parallel-group study[外文期刊]2002(9309)

34.Flint A;Raben A;Astrup A Glucagon-like peptide 1 promotes satiety and suppresses energy intake inhumans[外文期刊] 1998(3)

35.Tang-Christensen M;Larsen PJ;Coke R Central administration of GLP-I-(7-36) amide inhibits foodand water intake in rats 1996

36.Coke R;Larsen PJ;Mikkelsen JD Distribution of GLP-I binding sites in the rat brain:evidence thatexendin-4 is a ligand of brain GLP-I binding sites 1995

37.Nauek MA;Heimezaat MM;Hoist JJ Preserved incretin activity of glueagon-like peptide 1[7-36 amide]but not of synthetic human gastric inhibitory polypeptidc in patients with type-2 diabetes mellitus1993

38.Knop FK Reduced inosetin effect in type 2 diabetes:cause or consequence of the diabetic state[外文期刊] 2007(8)

39.Ding WG;Gromada J Protein kinase A-dependent stimulation of execytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide 1997

40.Toft-Nielsen MB;Damholt MB;Madsbad S Determinants of the impaired secretion of glucagon-likepeptide-1 in type 2 diabetic patients 2001

41.Kim S J;Winter K;Nian C GIP stimulation of pancreatic beta-cell survival is dependent uponpbosphatidylinositol 3-kinase (PI3-K)/ protein kinase B (PKB) signaling,inactivation of the forkheadtranscription factor Foxol and downregulation of bax expression 200542.Baggio LL;Drucker DJ Biology of lncretins:GLP-I and GIP[外文期刊] 2007(6)

43.Holz GG 4th;Kǖhtreiber WM;Habener JF Pancreatic beta-cells are rendered glucose-competent by theinsulinotropic hormone glucagun-like peptide-I (7-37) 1993

44.Salehi M;Aulinger BA;D'Alessio DA Targeting β-cell mass in type 2 diabetes:promise andlimitations of new drugs based on incretins 2008

45.Drucker D J;Nauck MA The incretin system:glucagonlike peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors in type 2 diabetes[外文期刊] 2006(9548)

本文链接：/Periodical_zhnfmdx201106025.aspx